AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03787628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) 600 mg
Description: CBD (300 mg) will be administered orally twice daily in the morning and again in the afternoon. The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml od CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
Study NCT03787628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. Different amounts (numbers of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 28 days.
Study NCT04591925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Device insulin infusion devcie
Description: Control Device - Commercially available insulin infusion device using a soft Teflon indwelling cannula
Study NCT04591925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigative insulin infusion devcie
Description: Investigative insulin infusion device with coil-reinforced soft polymer indwelling cannula
Study NCT06195995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation-true stimulus
Description: Three conductive electrodes are placed overhead. In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side. The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. The frequency of stimulation is 77.5Hz, and the current is 15mA.
Study NCT06242223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal HIIT
Description: multimodal HIIT protocol followed by sprinting followed by 2 minutes of rest, burpees with 3 minutes rest between sets and push ups 4-5 rep at 80-100% of HR max with a total of 20 minutes exercise per session a day 3 times a week followed by 6 weeks.
Study NCT06242223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional HIIT
Description: conve protocol with 4-5 repetitions of 40 seconds maximum running at 80-100% HR max followed by 20 seconds of walking for 20 minutes exercise per session 3 times a week followed by 6 weeks.
Study NCT06103487 — intervention group
Intervention type: GENETIC
Intervention: No Intervention
Description: Observational study
Study NCT05366478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous tumor infiltrating lymphocytes (TILs)
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.
Study NCT05235685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical air
Description: Exercise under medical air, both arms exposed.
Study NCT05235685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical air
Description: Exercise under medical air, both arms exposed.
Study NCT05027685 — intervention group
Intervention type: DEVICE
Intervention: The Paradise Ultrasound Renal Denervation System
Description: The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
Study NCT05235685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: Exercise under hyperoxia, only experimental arm exposed.
Study NCT01295099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5- fluorouracil
Description: 5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
Study NCT01295099 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: after complete excision of keloid they have a single session of radiotherapy
Study NCT01295099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: TAC 10mg in 1ml injected intralesional
Study NCT05890404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-Affirmative CBT Training: Materials Only
Description: Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment.
Study NCT05890404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-Affirmative CBT Training: Direct Training
Description: Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers.
Study NCT05890404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-Affirmative CBT Training: Local Supervision
Description: Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers. This arm will also receive one year of ongoing (at least monthly) supervision in LGBTQ-affirmative CBT from an expert supervisor at your center.
Study NCT06519448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 miligrams (mg)
Description: Use of empagliflozin 10 mg daily for 12 months.
Study NCT05224245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE Prime XL Transfemoral Aortic Valve System
Description: ACURATE Prime™ Transfemoral Aortic Valve system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
Study NCT06093152 — intervention group
Intervention type: DRUG
Intervention: Salbutamol
Description: Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.
Study NCT04590209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis
Study NCT04590209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
Study NCT06303128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 250 MG
Description: Liquid amoxicillin 250mg PO
Study NCT06303128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given prior to amoxicillin 250mg in one-dose group
Study NCT06303128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 62.5mg
Description: Given first in two-dose group, liquid amoxicillin 62.5mg PO
Study NCT06303128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 187.5mg
Description: Given second in two-dose group, liquid amoxicillin 187.5mg PO
Study NCT06238310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Comparison of two external marker substance for measuring glomerular filtration rate
Description: Two external marker substance compares for measuring GFR.
Study NCT06265623 — intervention group
Intervention type: OTHER
Intervention: No active intervention, but observational follow-up
Description: Patients remain in usual care by their pulmonary medicine specialists and are being observed during annual follow-up investigations during up to 3 years
Study NCT05932264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib + Fluzoparib
Description: Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid
Study NCT05932264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib + Fluzoparib + Adebrelimab
Description: Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w\]
Study NCT05707481 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Pharmacist-Led Educational Intervention
Description: Non Pharmacological management strategies include information related to life style modification, healthy dietary habits, physical activity and stress management techniques. In contrast, pharmacological educational intervention involves disease -related information ( diabetes/hypertension sign and symptoms, risk factor, complications, self-monitoring of blood pressure/glucose, symptoms and management of hypoglycemia/hypotension etc. ) and drug related information ( prescribed drug name, indication, contraindication, adverse effects etc.) as well as importance of adherence to prescribed medication and strategies to minimize DRPs issues. These teaching sessions will be carried out with the help of verbal communication, audio visual demonstration (including charts,pictorial etc) and information leaflets. Furthermore, a copy of educational package would be given to each participant for reference and guidance.
Study NCT05464498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Tissue Collagen Medical Device
Description: MD-Tissue (GUNA, Milan-Italy) Composition per 2 ml: collagen 100 micrograms Excipients: Ascorbic acid, Magnesium gluconate, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, NaCl, Water for injection.~Subjects will be treated with No. 6 peri-tendon injections (2 infiltrations per week for three weeks).
Study NCT05464498 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: eccentric strengthening protocol
Description: Group B which, will implement only physiotherapy (eccentric strengthening protocol)
Study NCT05464498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric strengthening protocol
Description: Group B which, will implement only physiotherapy (eccentric strengthening protocol)
Study NCT05883046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performance-Enhancing Substances
Description: All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
Study NCT05883046 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)
Study NCT05883046 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline (Control)
Description: No supplement conditions
Study NCT06414161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: mix of (green tea and peppermint)
Description: Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out \[27\].~The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben \[28\].~Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract.
Study NCT06414161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mix of (green tea and peppermint)
Description: Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out \[27\].~The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben \[28\].~Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract.
Study NCT05026541 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nap Practitioners
Description: Regular nappers will be given a 30 minute nap opportunity to nap for as long as they please.
Study NCT05026541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shoonya Meditation
Description: This is a 15 minute meditation, described as a process of conscious non-doing.
Study NCT04610736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Oral Suspension
Description: One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
Study NCT06510868 — intervention group
Intervention type: RADIATION
Intervention: Peptide receptor radionuclide therapy (PRRT)
Description: Specialized type of radionuclide therapy used to treat neuroendocrine tumors.
Study NCT06510868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Patients will have approximately 5 ml of blood drawn 6,12,24,36,48, 60 months and at the time of MDS/AML diagnosis on follow up. Genomic DNA will be extracted from serum sample using the Qiagen QIAamp DNA Mini Kit. Single-molecule molecular inversion probes (smMIPs) will be used to detect mutations. Single nucleotide variants (SNVs), short insertions and deletions (indels), and mutated myeloid genes will be captured (e.g PPM1D, DNMT3A, TET2, TP53).
Study NCT06065930 — intervention group
Intervention type: DEVICE
Intervention: Subcutaneous microdialysis
Description: Group with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.
Study NCT04997798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Pyrotinib Exemestane Dalpiciclib
Description: Early triple positive breast cancer patients receive combination regimen of Dalpiciclib in Combination With Exemestane and Trastuzumab plus pyrotinib
Study NCT06360276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated Exercises
Description: A quasi-experimental research was conducted in the main University Hospital, Alexandria, Egypt. women practiced seated exercises
Study NCT06360276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Rehabilitation
Description: Women received Psycho-educational Rehabilitation, including mindfulness breathing, problem-solving training, cognitive re-framing technique, and thought stopping.
Study NCT06360276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Women received routine health education in the unit, where nurses provided general instructions about the postoperative activities for women with breast cancer.
Study NCT06499116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Treatment will be prescribed for GPs and they will decide the specific dosage 25-100 mg/12h.
Study NCT06499116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flunarizine
Description: Treatment will be prescribed for GPs and they will decide the specific dosage 2,5-10 mg mg/24h.
Study NCT06499116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Treatment will be prescribed for GPs and they will decide the specific dosage 10-75 mg/24h.
Study NCT06499116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Treatment will be prescribed for GPs and they will decide the specific dosage 20-120 mg/12h.
Study NCT06507514 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: blinatumomab and auto-HSCT sandwich  strategy
Description: The patients received sequential infusion of blinatumomab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after infusion. Following successful stem cell collection, autologous stem cell transplantation was conducted. Starting from the third month after autologous stem cell transplantation, the second maintenance treatment with brentuximab vedotin was administered, with one cycle every three months, for a total of four cycles. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
Study NCT05544786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir/ ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
Study NCT05544786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/Ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition
Study NCT05544786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/Ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
Study NCT05544786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
Study NCT05544786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
Study NCT04759365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN51
Description: ASN51 formulation for oral capsule
Study NCT04759365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation for oral capsule
Study NCT06195449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALKASITE RESTORATIVE MATERIAL
Description: Restorative material for primary teeth
Study NCT06195449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer Cement
Description: Restorative material for primary teeth
Study NCT06234436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma exchenge
Description: Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
Study NCT05479149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training protocol with the cervical device for treatment (CDAT).
Description: Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
Study NCT05479149 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training protocol
Description: Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
Study NCT04514562 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeVa Stent Retrievers
Description: mechanical neurothrombectomy
Study NCT04090476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: During each of the exercise sessions the LSVT Big daily exercises will be performed along with functional tasks and gait/balance tasks. The functional tasks and gait/balance tasks will change weekly to monthly and all activities will be modified to the participant's mobility level.
Study NCT05044416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VieScope
Description: intubation with VieScope laryngoscope
Study NCT05044416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscopy
Description: intubation with videolaryngoscope
Study NCT06509321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subinguinal loupe-assisted varicocelectomy (LV)
Description: to assess the efficacy and safety of sub inguinal loupe-assisted varicocelectomy with nitroglycerin instillation as a vasodilator and compare its results versus subinguinal microscopic varicocelectomy
Study NCT06509321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subinguinal microscopic varicocelectomy (MV)
Description: we are using surgical microscope to perform varicocelectomy as control group
Study NCT06390449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kahoot intervention
Description: Kahoot, one of the WEB-2.0 tools, will be applied to students who are second-year students of the nursing department and taking the basic principles and practices in nursing course after the course.